AstraZeneca plc’s (AZN) Buy Rating Reaffirmed at Berenberg Bank
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Berenberg Bank in a report released on Thursday. They presently have a GBX 5,550 ($73.92) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price target would suggest a potential upside of 14.05% from the stock’s previous close.
Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. restated a “neutral” rating and set a GBX 4,800 ($63.93) price objective on shares of AstraZeneca plc in a report on Thursday, July 21st. Societe Generale set a GBX 7,000 ($93.23) price objective on AstraZeneca plc and gave the stock a “buy” rating in a report on Thursday. Jefferies Group boosted their price objective on AstraZeneca plc from GBX 4,600 ($61.27) to GBX 4,800 ($63.93) and gave the stock a “hold” rating in a report on Thursday, July 14th. BNP Paribas reiterated an “outperform” rating and issued a GBX 5,000 ($66.60) target price on shares of AstraZeneca plc in a report on Wednesday, June 15th. Finally, HSBC set a GBX 4,815 ($64.13) target price on AstraZeneca plc and gave the company a “neutral” rating in a report on Tuesday, August 2nd. Five analysts have rated the stock with a sell rating, thirteen have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of GBX 4,919.39 ($65.52).
AstraZeneca plc (LON:AZN) traded down 0.22% on Thursday, hitting GBX 4866.50. 2,038,270 shares of the stock were exchanged. The company’s market cap is GBX 61560.43 billion. The company’s 50 day moving average price is GBX 4,967.17 and its 200-day moving average price is GBX 4,294.47. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/08/astrazeneca-plcs-azn-buy-rating-reaffirmed-at-berenberg-bank.html
The business also recently disclosed a dividend, which will be paid on Monday, September 12th. Shareholders of record on Thursday, August 11th will be paid a dividend of GBX 68.70 ($0.92) per share. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related companies with MarketBeat.com’s FREE daily email newsletter.